Riesgo de acidosis láctica fatal y no fatal con el uso de metformina para la diabetes mellitus tipo 2
Characteristics of included studies Notes Allocation concealment
D
Study
Herman 1961
Methods
TRIAL DESIGN: Prospective cohort study DURATION: approximately 1 month
Participants
COUNTRY: South Africa SETTING: outpatient Treatment N: 47 Control N: 0 AGE: not listed SEX: not listed INCLUSION: maturity-onset DM, juvenile-onset patients were studied but not analysed EXCLUSIONS: none listed
Interventions
TREATMENT: Metformin 1.5-3 g/day COMPARISON: none
Outcomes
Fasting glucose and glucose tolerance.
Notes Allocation concealment
D
Study
Hermann 1991a
Methods
TRIAL DESIGN: Open-label randomised controlled trial DURATION: 6 months
Participants
COUNTRY: Sweden SETTING: outpatient Treatment N: 122 Control N: 45 AGE: 60 SEX: 64% men INCLUSION: Type 2 DM EXCLUSIONS: cardiac, renal or hepatic disease, alcohol abuse, severe chronic disease
Interventions
TREATMENT: Metformin 1 g BID or metformin + glibenclamide COMPARISON: glibenclamide
Outcomes
Fasting glucose, HbA1, weight.
Notes Allocation concealment
D
Study
Hermann 1991b
Methods
TRIAL DESIGN: Open-label crossover randomised controlled trial DURATION: 1 year
Página 54
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.